63290-17-5

Upstream product

• 62442-93-7 4-(tetradecyloxy)benzeneacetic acid methyl ester 
• 156-38-7 4-hydroxyphenylacetate 
• 112-71-0 1-Bromotetradecane 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 

Downstream Products

• 63290-16-4 4-(Tetradecyloxy)benzeneacetyl chloride 
• 869582-17-2 N-(2-hydroxyethyl)[4-(tetradecyloxy)phenyl]acetamide 
• 1026447-66-4 Methanesulfonic acid 3-{acetyl-[2-(4-tetradecyloxy-phenyl)-ethyl]-amino}-benzyl ester 
• 1027044-79-6 Methanesulfonic acid 4-[2-(4-tetradecyloxy-phenyl)-acetylamino]-benzyl ester 
• 1027901-56-9 Methanesulfonic acid 3-[2-(4-tetradecyloxy-phenyl)-acetylamino]-benzyl ester 
• 1027923-00-7 Methanesulfonic acid 2-[2-(4-tetradecyloxy-phenyl)-acetylamino]-benzyl ester 
• 1027263-66-6 Acetic acid 3-{acetyl-[2-(4-tetradecyloxy-phenyl)-ethyl]-amino}-benzyl ester 
• 144767-02-2 N-(3-Hydroxymethyl-phenyl)-N-[2-(4-tetradecyloxy-phenyl)-ethyl]-acetamide 
• 138830-27-0 N-(4-Hydroxymethyl-phenyl)-2-(4-tetradecyloxy-phenyl)-acetamide 
• 138830-28-1 N-[4-(Bromomethyl)phenyl]-4-(tetradecyloxy)-benzeneacetamide 
• 138830-25-8 N-<3-(hydroxymethyl)phenyl>-4-(tetradecyloxy)benzeneacetamide 
• 138830-26-9 N-[3-(Bromomethyl)phenyl]-4-(tetradecyloxy)-benzeneacetamide 
• 139907-03-2 N-[2-(Bromomethyl)phenyl]-4-(tetradecyloxy)-benzeneacetamide 
• 139907-02-1 N-[(2-Hydroxymethyl)phenyl]-4-(tetradecyloxy) benzeneacetamide 

Relevant academic research and scientific papers

Inhibition of secretory phospholipase A2. 1-Design, synthesis and structure-activity relationship studies starting from 4- tetradecyloxybenzamidine to obtain specific inhibitors of group II sPLA 2s

Starting from 4-tetradecyloxybenzamidine (PMS815), a non-specific inhibitor of GI and GII PLA2s, we report in this work the discovery of the specificity through design, synthesis and structure-activity relationships studies of different kinds o

Pyridinium compounds which are useful as antagonists of platelet activating factor

The invention is aryl, amide, imide and carbamate pyridine antagonists of platelet activating factor.

Bis-aryl amide and urea antagonists of platelet activating factor

Bis-aryl amide and urea compounds of the general formula: STR1 wherein X is a divalent amide or urea substituent and Y is a nitrogen containing heterocycle, which compounds are inhibitors of platelet activating factor. Pharmaceutical compositions containing the compounds and methods of treating platelet activating factor associated conditions are also included.

Analogues of platelet activating factor. 7. Bis-aryl amide and bis-aryl urea receptor antagonists of PAF

A series of bis-aryl amide (13-57 and 66-81) and bis-aryl urea (58 and 85) antagonists of platelet-activating factor (PAF) was prepared that contain, separating the two aromatic rings, linear amide linkages of the form - (CH2)(n)CONH- (n = 0-2), -OCH2CONH-, and -(CH2)(n)NHCO- (n = 0-1), branched amide linkages of the form -(CH2)(n)N(COR)- (n = 1-3, R = CH3 or n-C3H7), and -N(COCH3)CH2-, and urea linkages of the form -NHCONH- and - CH2N(CONHCH3)-. These compounds were examined for their ability to inhibit PAF-induced platelet aggregation of rabbit platelets. These in vitro data were compared to similar data obtained for a number of known PAF antagonists. The compounds were evaluated in vivo, in the mouse, for their ability to prevent death induced by a lethal challenge of PAF. The relationships between the biological activity and the nature, lipophilicity, and position of substituents of the aromatic rings were studied. Best activity was observed for compounds having linkages of the type -CH2CONH-, -CH2N(COR)-, and - CH2NHCO-. Many of these compounds inhibit PAF-induced platelet aggregation with IC50's under 1 μM.

Method of preparing bis-aryl amide and urea antagonists of platelet activating factor

Methods of preparing bis-aryl amide and urea compounds of the general formula: STR1 wherein x is a divalent amide or urea substituent and Y is a nitrogen containing heterocycle, which compounds are inhibitors of platelet activating factor.

Phosphocholine derivatives having antihypertensive action

Phosphocholine derivatives and compositions are described which are useful as hypotensive agents and in the treatment of hypertension in warm-blooded animals.